Our Company
We are an experienced team with internal drug discovery and development expertise focused on building a pipeline of best-in-class oral drugs for liver and gastrointestinal diseases.
Focused on developing innovative drugs that materially benefit patients with liver and gastrointestinal diseases
Non-alcoholic steatohepatitis (NASH) is one of the most common liver diseases
Inflammatory bowel disease is increasing in prevalence worldwide
Metacrine is building a pipeline of novel therapeutics for NASH and GI disease
Programs
Our lead program is a portfolio of optimized next generation FXR agonists for the treatment of non-alcoholic steatohepatitis (NASH) and inflammatory bowel diseases. Beyond our FXR program, we are focused on building a pipeline of other novel drug candidates including HSD17B13 and SSAO/VAP-1.